Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Water Oasis Group Ltd
HKEX:1161
|
HK |
|
G
|
GFoot Co Ltd
TSE:2686
|
JP |
|
C
|
China Fordoo Holdings Ltd
HKEX:2399
|
CN |
Bioventus Inc
Long-Term Debt
Bioventus Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Long-Term Debt
$287.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Long-Term Debt
$920m
|
CAGR 3-Years
7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
9%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Long-Term Debt
$1.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
251%
|
CAGR 10-Years
N/A
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Long-Term Debt
$568.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
24%
|
CAGR 10-Years
5%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Long-Term Debt
$734m
|
CAGR 3-Years
58%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Long-Term Debt?
Long-Term Debt
287.7m
USD
Based on the financial report for Dec 31, 2025, Bioventus Inc's Long-Term Debt amounts to 287.7m USD.
What is Bioventus Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
11%
Over the last year, the Long-Term Debt growth was -9%. The average annual Long-Term Debt growth rates for Bioventus Inc have been -9% over the past three years , 11% over the past five years .
